CC 8464

Drug Profile

CC 8464

Alternative Names: ASP 1807; CC 8464

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chromocell Corporation
  • Class Analgesics
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Diabetic neuropathies; Osteoarthritis; Sciatica

Most Recent Events

  • 12 Oct 2016 Phase-I clinical trials in Neuropathic pain in USA (PO) before October 2016
  • 12 Oct 2016 CC 8464 receives Fast Track designation for Neuropathic pain [PO] in USA
  • 01 Jul 2016 Chromocell Corporation files an IND application with the US FDA in USA for Neuropathic pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top